deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT02131272

A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin (iDEAt2)

A 26-week Open Label, Randomised, 2-armed, Parallel Group, Multi-centre Trial Investigating Efficacy and Safety of Insulin Detemir Versus Insulin Neutral Protamine Hagedorn in Combination With the Maximum Tolerated Dose of Metformin and Diet/Exercise on Glycaemic Control in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on the Maximum Tolerated Dose of Metformin ± Other Oral Antidiabetic Drug(s) ± Basal Insulin

Sponsor: Novo Nordisk A/S

Conditions Diabetes Diabetes Mellitus, Type 2
Interventions Diet/exercise Insulin NPH Insulin detemir
Updated 11 times since 2017 Last updated: Aug 9, 2018 Started: Jun 11, 2014 Primary completion: Jun 14, 2016 Completion: Jun 14, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Novo Nordisk A/S

See all terminations from Novo Nordisk A/S

Other Diabetes trials with similar outcome

Browse all Diabetes trials

This PHASE3 trial investigates Diabetes and Diabetes Mellitus, Type 2 and is currently terminated or withdrawn. Novo Nordisk A/S leads this study, which shows 11 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Oct 2017 · 8 months · monthly snapshotCompleted~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshotTerminated~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshotTerminated~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshotTerminated~Oct 2018 – ~Jan 2021 · 27 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotTerminated~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 11 months · monthly snapshotTerminated

Change History

11 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  4. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE3

  5. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE3

▶ Show 6 earlier versions

  1. Oct 2018 — Jan 2021 [monthly]

    Terminated PHASE3

  2. Aug 2018 — Oct 2018 [monthly]

    Terminated PHASE3

  3. Jun 2018 — Aug 2018 [monthly]

    Terminated PHASE3

  4. Oct 2017 — Jun 2018 [monthly]

    Terminated PHASE3

    Status: Completed → Terminated

  5. Feb 2017 — Oct 2017 [monthly]

    Completed PHASE3

  6. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Jun 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novo Nordisk A/S
Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adana, Turkey (Türkiye) , Ahmedabad, India , Alexandria, Egypt , Amarillo, United States , Ancona, Italy , Ankara, Turkey (Türkiye) , Aparecida de Goiânia, Brazil , Atlanta, United States , Bangalore, India , Beersheba, Israel and 63 more locations